Articles from SPR Therapeutics, Inc.

CLEVELAND, Jan. 30, 2025 (GLOBE NEWSWIRE) -- SPR announces four featured abstracts that will be presented at the upcoming North American Neuromodulation Society (NANS) Annual Meeting in Orlando, January 29 – February 1. All the abstracts contain recent clinical data and insights highlighting the utility of the SPRINT PNS System in the treatment of pain.

CLEVELAND, Dec. 13, 2024 (GLOBE NEWSWIRE) -- SPR Therapeutics has been named to the Crain’s Cleveland Business Fast 50, placing first on the list of rapidly growing, privately held companies ranked by revenue growth over the last five years.

Presentations include first reporting of data for the RESET™ Clinical Trial evaluating SPRINT PNS versus Standard Interventional Management for low back pain

CLEVELAND, Nov. 18, 2024 (GLOBE NEWSWIRE) -- For over 30 years, Crain’s Cleveland Business has recognized leading professionals in the Northeast Ohio region that have been celebrated as part of the 40 Under 40 program. This year, SPR Therapeutics Chief Financial Officer and Chief Operating Officer Ben Austin has been selected as one of the outstanding honorees.

- Holistic approach to measurement provides meaningful real-world impact evaluation -

Five total abstracts presented at ASPN 2024

- Corporate culture remains a strength as the company experienced dynamic growth -

CLEVELAND, June 11, 2024 (GLOBE NEWSWIRE) -- SPR® Therapeutics, a leader in the use of peripheral nerve stimulation (PNS) to address different types of pain throughout the body, announced the publication of a review of prospective studies evaluating the impact on chronic pain following percutaneous PNS treatment. Published in Pain Management, the review identified studies evaluating PNS treatment for three primary treatment applications: low back pain, shoulder pain, and neuropathic pain. Studies included in the review all utilized treatment with short-term percutaneous PNS for up to 60 days with leads placed to target participants’ specific pain.

Pain Relief Resulted in Improved Objective Measure of Walking Ability at End of Treatment

Pain Relief Resulted in Improved Objective Measure of Walking Ability at End of Treatment

CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients managing acute or chronic pain, today announced that it has secured $85 million in financing including $25 million in Series D-1 insider equity and a $60 million debt facility. The equity financing was led by Revelation Partners, SPR’s lead investor of the Series D equity financing, and incumbent investors, RC Capital and Mutual Capital Partners. The debt facility is provided by SLR Capital Partners and Armentum Partners served as the Company’s financial advisor.

- Data presented features nerve targets throughout the body, highlighting the versatility of the SPRINT® PNS System -

- RESET is the largest prospective, multicenter randomized controlled trial of SPRINT PNS conducted to date -

Three Posters Accepted Including a President’s Choice Award for New Data from a Randomized Controlled Trial on Total Knee Replacement Postoperative Pain

Commercial expansion and real-world evidence results in doubling of total implants in just over a year

- Company maintains focus on employee engagement and success while experiencing dynamic growth -

CLEVELAND, May 17, 2023 (GLOBE NEWSWIRE) -- SPR® Therapeutics announced the publication of a comprehensive real-world retrospective data analysis of over 6,100 patients demonstrating significant pain relief following 60-day percutaneous peripheral nerve stimulation (PNS) treatment with the SPRINT® PNS System in the journal Pain Physician.

CLEVELAND, May 04, 2023 (GLOBE NEWSWIRE) -- SelectHealth, a non-profit health plan with over one million members, has demonstrated leadership amid the opioid crisis by creating one of the first coverage policies supporting the use of Peripheral Nerve Stimulation (PNS). SPR Therapeutics is pleased to see this occur at a time when PNS, such as that delivered by the SPRINT® PNS System, is fast becoming a leading and mainstream non-opioid treatment for chronic pain. With more than thirty peer-reviewed publications supporting the use of SPRINT PNS across a wide range of pain conditions, SelectHealth is taking steps to assure access for their members to this FDA-cleared treatment as well as other PNS treatments.

CLEVELAND, Ohio, April 25, 2023 (GLOBE NEWSWIRE) -- SPR® Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients managing acute or chronic pain, announced the introduction of the SPRINT extensa XT System with bimodal peripheral nerve stimulation (PNS), designed to deliver a comprehensive approach to the alleviation of pain by treating dual nerve targets with synergistic stimulation modalities.

CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients suffering from acute or chronic pain, announced the peer-reviewed publication of final patient-reported outcomes from the largest prospective, multicenter trial completed to date of temporary peripheral nerve stimulation (PNS) for chronic low back pain.

CLEVELAND, Feb. 03, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients managing acute or chronic pain, announced it has obtained clearance from the U.S. Food and Drug Administration (FDA) for expanded labeling, which increases the intended patient population of the SPRINT® PNS System, along with new advances to enhance and simplify the SPRINT PNS System’s lead securement mechanism.

One of six total abstracts accepted highlighting benefits of the SPRINT® PNS System